



UNIVERSITY OF SOUTH FLORIDA

Purchasing Services
Mail Stop SVC 1073
4202 East Fowler Avenue
Tampa, Florida 33620
(813) 974-2481

Web Site: <http://www.usf.edu/business-finance/purchasing/staff-procedures/index.aspx>

November 7, 2016

| | |
|------------------------------------|--|
| Invitation to Negotiate No. | 17-08-MH |
| Entitled: | Teddy Study RNA Sequencing Laboratory |
| Opening Date: | December 08, 2016 at 3:00 p.m. |

Addendum No. 2

Review the following changes/additions/clarifications to Invitation to Negotiate (ITN) No. 17-08-MH TEDDY Study RNA Sequencing Laboratory to be addressed in submitted proposals:

Vendor Questions for ITN 17-08-MH – TEDDY RNA Sequencing Lab

1. We were looking for clarification on Page 19, Item #5 - "5. Evidence that your facility can accomplish the work outlined in the requirements within the time frame, given the volume of work already committed."
Response: This is referring to the Statement of Work and Requirements detailed on pages 17-18 of the ITN.
2. Could you provide a little bit more information on the sort of evidence that would be convincing that we can accomplish the work? Are you looking for previous studies?
Response: Examples of previous work would be sufficient as well as a thorough description of your capabilities to accomplish the requirements detailed on pages 17-18 of the ITN.

3. Page 19, Item #8 "Please provide a total budget and a budget for each fiscal year of the contract as follows: • March 2017 to March 2018"

Response: This project will be for one year, please provide a budget for this one year period.

4. Additionally, Page 18, Item #7 "The ultimate number of samples will depend on the experiments proposed. Since this will be a cost reimbursement subcontract, laboratories must indicate a budget on a cost/sample basis. It is however expected that some component of the project will have a budget that will not significantly change with the number of samples (e.g. publications, datamodeling and interpretation) and therefore might not follow the cost/sample model.

- a. Can you provide a little more information on what how to present the budget. We can handle a cost per sample, but it's definitely hard to provide a yearly budget without a total number of samples. Would an estimated number of samples work for this? Or perhaps just leave the cost as cost per sample?

Response: A cost per sample budget is sufficient; we estimate that there will be a total of 5,296 samples sent to the lab.

5. What is the Sample Type? Serum, Plasma, Total RNA, Tissue, Cells, Whole blood, FFPE

Response: Total RNA.

6. The number of Samples? On page 16 of the ITN No: 17-08-MH, states 5296 samples. Will all the samples come at once, or throughout the year? If throughout the year, what is the estimated monthly frequency?

Response: There will be approximately 5,296 total samples; the shipment frequency will be determined at a later time.

7. Has Heparin been avoided in the collection protocol?

Response: Yes.

8. We understand that the samples are stored and available as extracted RNA. Can you provide further information on the amount of RNA available and the average quality (eg DV200 scores)?

Response: This will be assessed at a later time.

9. Will the entire amount of RNA be shipped to the vendor or will we be receiving an aliquot? If this is the case can 500ng of RNA be made available?

Response: This will be determined at a later time.

10. Your protocols request small RNA sequencing - would a total RNA approach be acceptable?

Response: Yes.

11. It is possible to have more details (project aims and research questions) with regards to the research programs under TEDDY that plan to incorporate transcriptomics analysis? This is to help us explore potential areas in which we could dove-tail specific analysis solutions to research goals & questions.

Response: It is a case control study and longitudinal samples are available from an individual and the plan is to use RNA-Seq approach to identify differentially expressed transcripts etc. between autoantibody subjects and autoantibody negative subjects, diabetic subjects and non-diabetic subjects as well changes for one along the way to autoantibody positivity and diabetes.

12. Can you provide the policies for the following:

- a. Summarize and interpret results of the analyses for publications in accordance to TEDDY publications policies and procedures.

Response: The policy will be provided and discussed once the award is made.

13. The RFP requests a broad range of analysis requirements for the project – is there a priority order for the analysis options from the following list –

- a. catalogue all species of transcript, including mRNAs, non-coding RNAs and small RNAs;
- b. to determine the transcriptional structure of genes, in terms of their start sites, 5' and 3' ends, splicing patterns and other post-transcriptional modifications;
- c. and to quantify the changing expression levels of each transcript during development and under different conditions.

Response: Letters a and c have a higher priority than letter b.

Note: Please note receipt of this addendum by signing and returning with your proposal response

Authorized Signature & Date

Print Name

Company Name